Article Sidebar

Submitted
October 31, 2023
Accepted
March 27, 2024
Published
May 2, 2024
Download
PDF
Statistic
Read Counter : 25 Download : 9

Downloads

Download data is not yet available.

Main Article Content

Abstract

The validation analytical method of the Lapatinib ditosylate assay is crucial to increase testing capability and capacity in strengthening the supervision of post-marketing drugs in Indonesia. A fast, precise, accurate, valid, and efficient test method is needed to carry out the test. A previous study on determining Lapatinib ditosylate assay generally used a C18 column, yet for efficiency, it is also necessary to develop a test method that can use existing resources in the laboratory, where the research used a C8 column. In this study, an analytical method to determine the assay of Lapatinib ditosylate developed using a High-Performance-Liquid Chromatography-Diode Array Detector (HPLC-DAD) system equipped with an autosampler and XBridge ® C8 column (Waters); 250 x 4.6 mm i.d. 5 μm. The mobile phase consisted of pentane-1-sulfonic acid sodium salt 10 mM - acetonitrile (65:35) eluted isocratically at a 0.6 mL/min flow rate. Detection was carried out at a wavelength of 222 nm. The analytical method was validated with test parameters of selectivity, system suitability, accuracy, precision, linearity, detection limit and quantification limit. Results from the validation study demonstrated a retention time of 4.63 minutes, good linear in the concentration range of 0.06 – 0.18 mg/mL with a correlation coefficient and Vx0 of 1.00000 and 0.1%. Test accuracy (% bias) obtained a value of 0.77% with precision (system, method and intermediate) less than 2.0%. The detection and quantification limits were 0.67 µg/mL and 2.02 µg/mL. Based on the research results, it can be concluded that the method developed provides fast, accurate and valid performance. Validation of the Analytical Method for Determining Lapatinib Ditosylate Raw Material Contents using HPLC-DAD.

Keywords

Lapatinib ditosylate HPLC-DAD assay validation Lapatinib ditosylate KCKT-DAD penetapan kadar validasi

Article Details

How to Cite
Nopi, N. S., & Isnaeni, N. (2024). Validation of the Analytical Method for Determining Lapatinib Ditosylate Raw Material Contents using HPLC-DAD. Eruditio : Indonesia Journal of Food and Drug Safety, 4(1), 33–42. https://doi.org/10.54384/eruditio.v4i1.178
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. Albiol-Chiva, J., Esteve-Romero, J., & Peris-Vicente, J. (2018). Development of a method to determine axitinib, lapatinib and afatinib in plasma by micellar liquid chromatography and validation by the European Medicines Agency guidelines. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 1074–1075(January), 61–69. https://doi.org/10.1016/j.jchromb.2017.12.034
  2. AOAC. (2002). AOAC Guidelines for Single Laboratory Validation of Chemical Methods for Dietary Supplements and Botanicals. AOAC.
  3. AOAC. (2019). Appendix K, AOAC Official Methods of Analysis: Guidelines for Dietary Supplements and Botanical. AOAC International, 1–9.
  4. Biswal, S., & Mondal, S. (2019). Analytical Method Validation Report for Assay of Lapatinib by UPLC. Pharmaceutical Methods, 10(1), 09–14. https://doi.org/10.5530/phm.2019.1.2
  5. Choudhary, A. (2019). Difference between C8 and C18 Columns Used in HPLC System. https://www.pharmaguideline.com/
  6. Government of India Ministry of Health. (2018). The Indian Pharmacopoeia (8th ed.). Indian Pharmacopoeia Commission.
  7. Haribabu, B., Krishna, K. B. M., & Krishnaveni, P. R. (2011). Development and Validation of HPLC Method for the Estimation of Lapatinib in Bulk Drugs and Pharmaceutical Formulations. International Journal of Research and Reviews in Pharmacy and Applied Sicences, 1(4), 207–214.
  8. https://www.medchemexpress.com/Lapatinib-ditosylate.html, diakses pada 21 April 2022.
  9. https://cekbpom.pom.go.id/, diakses pada 20 April 2022.
  10. ICH. (2021). ICH Harmonised Guideline - Impurities: Guideline for Residual Solvents Q3C(R8). April, 1–43.
  11. ICH. (2022). ICH Guideline Q2(R2) on Validation of Analytical Procedures Step 2b. 2(0).
  12. ICH. (2005). Validation of Analytical Procedures : Text and Methodology Q2(R1). ICH Harmonised Tripartite Guideline, 1–13. https://doi.org/10.1002/9781118532331.ch23
  13. Ivaturi, R., Sastry, T. M., & Sunkara, S. (2017). Development and Validation of Stability Indicating HPLC Method for the Determination of Lapatinib Impurities in Bulk and Finished Formulation. International Journal Pharmaceutical Sciences and Research, 8(7), 3081–3091. https://doi.org/10.2174/1573412914666180914163419
  14. Kanat, O., Ertas, H., & Caner, B. (2018). Dual HER2 inhibition strategies in the management of treatment-refractory metastatic colorectal cancer: History and status. World Journal of Clinical Cases, 6(11), 418–425. https://doi.org/10.12998/WJCC.V6.I11.418
  15. Kementerian Kesehatan Republik Indonesia. (2014). Farmakope Indonesia V.
  16. Kumar, K. K., Venkata Nadh, R., & Nagoji, K. E. V. (2012). A Validated RP HPLC Method for the Estimation of Lapatinib in Tablet Dosage form using Gemcitabine Hydrochloride as an Internal Standard. Indian Journal of Pharmaceutical Sciences, 74(6), 580–583.
  17. Linsinger, T. P. J., Pauwels, J., Van Der Veen, A. M. H., Schimmel, H., & Lamberty, A. (2001). Homogeneity and stability of reference materials. Accreditation and Quality Assurance, 6(1), 20–25. https://doi.org/10.1007/s007690000261
  18. Maung, K., & O’Shaughnessy, J. A. (2004). Inhibition of ErbB1 and ErbB2 by lapatinib ditosylate, a dual kinase inhibitor: Promising activity in pretreated advanced breast cancer. Clinical Breast Cancer, 4(6), 398–400. https://doi.org/10.1016/S1526-8209(11)70826-6
  19. National Cancer Institute. (2020). Lapatinib Ditosylate. Definitions, 32388. https://doi.org/10.32388/iaxws7
  20. Saadat, E., Kelishady, P. D., Ravar, F., Kobarfard, F., & Dorkoosh, F. A. (2015). Development and Validation of Rapid Stability-Indicating RP-HPLC-DAD Method for the Quantification of Lapatinib and Mass Spectrometry Analysis of Degraded Products. Journal of Chromatographic Science, 53(6), 932–939. https://doi.org/10.1093/chromsci/bmu150
  21. Shprakh, Z. S., Poskedova, Y. A., & Ramenskaya, G. V. (2022). Modern Instrumental Methods for Qualitative and Quantitative Analysis of Lapatinib in Biological Fluids and Dosage Forms (Review). International Journal of Applied Pharmaceutics, 14(1), 7–12. https://doi.org/10.22159/ijap.2022v14i1.42992
  22. Singh, R. (2013). Hplc Method Development and Validation: an Overview. J Pharm Educ Res, 4(1), 26–33.